Tag: source

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

HAINING, China, June 06, 2025 (GLOBE NEWSWIRE) -- Broadway Technology Inc (“Gaokai”), a leading manufacturer of high-quality PET (polyethylene terephthalate) cups and lids through its operating subsidiary Zhejiang Gaokai New Materials Co., Ltd., announced the execution of an Agreement and Plan of Merger (the “Merger Agreement”) for a business combination with Quartzsea Acquisition Corporation (Nasdaq: QSEAU, QSEA, QSEAR) (“Quartzsea”), a publicly traded special purpose acquisition company.

CALGARY, Alberta and TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Magnetic North Acquisition Corp. (TSXV: MNC; MNC.PR.A) (“Magnetic North” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on May 9, 2025 (the “MCTO”) by its principal regulator, the Alberta Securities Commission, under National Policy 12-203 - Management Cease Trade Orders (“NP 12-203”), following the Company’s announcement on May 8, 2025 (the “Default Announcement”) that it was unable to file its audited annual financial statements, ‎management’s discussion and analysis and related certifications for the year ended December ‎‎31, 2024 (the “Documents”) ‎on or before April 30, 2025, as required under applicable securities laws. The Company still expects to file the Documents by June 30, 2025.

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (Nasdaq: OPEN) (the “Company,” “Opendoor,” “we,” “our” or “us”), a leading e-commerce platform for residential real estate transactions, filed a preliminary proxy statement. The proxy statement was furnished in connection with the solicitation of proxies by Opendoor’s Board of Directors (the “Board”) for use at the Company’s Special Meeting of Stockholders to be held on Monday, July 28, 2025, at 9:30 a.m. Pacific Time.

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company’s umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain.

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the closing of its previously announced non-brokered private placement for gross proceeds of $4,905,150 - consisting of $3,555,150 of Units and $1,350,000 of Debenture Units (each as defined below).

With sincere enthusiasm and unwavering devotion to providing rewarding, innovative, and truly thrilling memories, SlotoCash is excited to unveil a broader collection of real-money online slots.